Hims & Hers’ Australia Expansion Adds Growth, But Execution Will Be Key
Hims & Hers Health, Inc. (NYSE: HIMS ) has entered Australia, marking its first expansion into the Asia-Pacific market. The move follows its acquisition of Australian digital-health platform Eucalyptus, which includes men's health brand Pilot and women's health brand Juniper. Hims is initially rolling out weight-loss and men's health treatments, with plans to introduce women's health services later this year.
Australia could become another meaningful growth engine for Hims & Hers Health, Inc. (NYSE:HIMS) as the company expands beyond its core U.S. market. The acquisition of Eucalyptus gives Hims an established local presence, existing brands and clinicians, which should reduce some of the execution risk normally associated with entering a new country.
The Australian market could also strengthen Hims' international scale. The company has already expanded into Europe through its acquisition of Zava, and Australia provides another market in which the company can leverage its technology, brand and telehealth infrastructure. If Hims & Hers Health, Inc. (NYSE:HIMS) can successfully replicate its customer-acquisition model internationally, the Australian business could become an important contributor toward its long-term $6.5 billion revenue target for 2030.
The weight-loss opportunity is another important upside. Hims plans to provide access to branded GLP-1 medicines in Australia, including drugs such as Wegovy and Zepbound. This allows the company to participate in the growing obesity-treatment market while using its platform to connect patients with clinicians and treatments.
The biggest concern is that international expansion can generate revenue without immediately producing attractive profitability. Hims & Hers Health, Inc. (NYSE:HIMS) has acknowledged that international growth has weighed on gross margins, and management expects margins to remain below historical levels as it continues investing in international offerings. Australia could therefore increase sales while initially pressuring earnings.
There is also no guarantee that Hims' U.S. customer-acquisition model will translate directly to Australia. The company will need to build brand awareness, acquire customers, and establish itself against local healthcare providers and digital-health platforms. Spending heavily on marketing before achieving sufficient scale could make the Australian operation less profitable than the mature U.S. business.
The GLP-1 opportunity also carries execution and competitive risks. Hims & Hers Health, Inc. (NYSE:HIMS) will be offering branded drugs rather than relying solely on its previous compounded-drug model, meaning its economics can depend more heavily on drug pricing, availability, and relationships with pharmaceutical companies. The company is also expanding into several healthcare categories at the same time, which increases operational complexity.
Finally, Hims is pursuing an aggressive international expansion strategy while simultaneously investing in diagnostics, manufacturing, hormonal treatments and other areas. The more capital and resources directed toward new markets, the longer it may take for those investments to translate into meaningful incremental profits. The key question is therefore whether Australia can eventually reach sufficient scale to justify the upfront costs.
While we acknowledge the potential of HIMS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .
READ NEXT: Cheniere Energy: Corpus Christi Expansion Strengthens Its LNG Growth Outlook and Venezuela's Energy Reopening Could Benefit Chevron (CVX) and GE Vernova (GEV), But Risks Remain
